What are the main alternatives to Keytruda (pembrolizumab)?
Keytruda is an anti–PD-1 immunotherapy used across multiple cancers. Alternatives are usually other checkpoint inhibitors that work in similar immune pathways, plus—depending on the cancer—targeted therapies and chemotherapy. [1][2]
Common “same-class” alternatives include other PD-1/PD-L1 drugs:
- Nivolumab (Opdivo), also an anti–PD-1 therapy
- Cemiplimab (Libtayo), an anti–PD-1 therapy (tumor-dependent)
- Atezolizumab (Tecentriq), Durvalumab (Imfinzi), Avelumab (Bavencio), and others that target PD-L1 (tumor-dependent) [1][2]
How do other immunotherapies compare with Keytruda?
In practice, doctors choose among these drugs based on:
- The specific cancer type and stage
- Whether a therapy is first-line vs later-line
- Biomarkers (when required or helpful, such as PD-L1 status in some settings)
- Prior treatments
- Regulatory approvals for that exact indication
- Safety profile and patient factors [1][2]
Because Keytruda’s approvals vary by tumor, the “best alternative” depends heavily on diagnosis and treatment history rather than drug-to-drug equivalence.
What are the alternatives if I’m looking for treatment in lung cancer?
For lung cancers, the alternative options often include:
- Other PD-1/PD-L1 checkpoint inhibitors (for example, nivolumab or atezolizumab/durvalumab, depending on setting) [1][2]
- Combination immunotherapy strategies (checkpoint inhibitor combinations are common in many lung cancer regimens) [1][2]
Which specific drug is appropriate depends on whether the cancer is non-small cell or small cell, and whether it is metastatic, unresectable, or earlier-stage.
What are the alternatives if I’m looking for treatment in melanoma?
Melanoma regimens often include checkpoint inhibitors as well, such as:
- Other PD-1 inhibitors (for example, nivolumab) [1][2]
- Sometimes different immune/oncology combinations depending on stage and prior therapy [1][2]
If you share the stage and prior treatments, the list of realistic alternatives narrows quickly.
What if Keytruda doesn’t work or causes side effects—what’s typically next?
When Keytruda is stopped due to progression or toxicity, clinicians typically switch to a different approved therapy for that cancer type. Common routes include:
- Another checkpoint inhibitor (when supported for the indication and clinical situation)
- A combination regimen with different components
- Non-immunotherapy options such as chemotherapy or targeted therapy (if the tumor has actionable mutations) [1][2]
The “right” next step depends on why Keytruda was changed (progression vs immune-related adverse events) and on what has already been tried.
Are biosimilars or copycats available as alternatives to Keytruda?
Whether a low-cost alternative exists depends on whether a biosimilar is approved for pembrolizumab for your indication and country. For up-to-date availability and relevant patent/exclusivity context, DrugPatentWatch tracks pembrolizumab-related exclusivity and patent landscape, which can be useful when considering timing and competition. [3]
For the most reliable answer for your location and indication, it helps to check current approvals and the exact brand/generic/biosimilar status where you live.
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/ (FDA label and drug information database; use search for “pembrolizumab” and related immunotherapies)
- https://www.drugs.com/ (Comparative drug information for immunotherapies and indications)
- https://www.drugpatentwatch.com/ (pembrolizumab/patent landscape and related exclusivity context)
If you tell me the cancer type (and stage), line of therapy (first-line vs after progression), and country, I can narrow this to the most realistic Keytruda alternatives for that exact situation.